Foghorn Therapeutics Inc. is a clinical stage precision therapeutics biotechnology company pioneering a new class of medicines that treat serious diseases by correcting abnormal gene expression through selectively targeting the chromatin regulatory system. The company focuses on oncology with potential applications in immunology and inflammation, leveraging its proprietary Gene Traffic Control platform to identify and validate targets within this system. Foghorn Therapeutics Inc. develops small molecule product candidates including enzyme inhibitors, protein degraders, and transcription factor disruptors to address genetically determined dependencies in cancer and other diseases.

Foghorn Therapeutics Inc. generates revenue primarily through strategic collaborations, most notably its partnership with Eli Lilly and Company. Under the Lilly Collaboration Agreement, the company received an upfront payment of $300.0 million and a concurrent $80.0 million equity investment. Foghorn Therapeutics Inc. is eligible to receive development and commercialization milestones, tiered royalties on product sales, and a share of U. S. profits for co-commercialized products directed to the SMARCA2-selective program and an additional undisclosed oncology target. The company also has the option to participate in the U. S. economics for three additional discovery programs under the collaboration.

The company operates through the following segments: Precision Oncology Pipeline and Platform Expansion Beyond Oncology.

• The Precision Oncology Pipeline segment focuses on developing product candidates targeting genetically determined dependencies within the chromatin regulatory system in cancer, including the lead candidate FHD-909, a first-in-class oral SMARCA2 selective inhibitor currently in Phase 1 clinical development for non-small cell lung cancer, as well as proprietary enzymatic inhibitors, protein degraders, and disruptors targeting disclosed targets such as SMARCA2, CBP, EP300, and ARID1B.

• The Platform Expansion Beyond Oncology segment aims to harness the Gene Traffic Control platform to develop novel product candidates for therapeutic areas outside oncology, such as immunology, inflammation, virology, autoimmune disease, and neurology, based on the chromatin regulatory system's role as an orchestrator of gene expression across a wide spectrum of diseases.

Foghorn Therapeutics Inc. holds a unique position in the biotechnology industry as, to its knowledge, the only company with the ability to study and target the chromatin regulatory system at scale, in context, and in an integrated way. This competitive advantage stems from its proprietary Gene Traffic Control platform, which enables target identification and validation, production of chromatin regulatory system components at scale, discovery and optimization of chemical matter, development of targeted protein degraders, and translation to clinic with biomarker identification. The company faces competition from major pharmaceutical and biotechnology firms pursuing similar mechanisms, including Arvinas, C4 Therapeutics, Kymera Therapeutics, Nurix Therapeutics, and others developing protein degradation approaches or targeting the chromatin regulatory system, but believes its biological insights and platform capabilities provide differentiation.

Foghorn Therapeutics Inc. serves patients with serious diseases, particularly those with genetically determined dependencies in the chromatin regulatory system, focusing initially on oncology patient populations such as those with non-small cell lung cancer and other solid tumors harboring SMARCA4 mutations, as well as patients with EP300-dependent cancers, CBP-mutant cancers, and ARID1A-mutated cancers across indications including endometrial, gastric, bladder, colorectal, breast, and hematologic malignancies.